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Introduction
Among oral therapies for motor symptoms of Parkinson's disease (PD), levodopa (LD) taken in combination with a peripheral dopa-decarboxylase inhibitor, such as carbidopa (CD), continues to be the gold standard [1, 2] . However, as PD progresses, patients using CD-LD as an immediate-release (IR) formulation often experience motor complications, including -on‖/-off‖ fluctuations and dyskinesias [1] [2] [3] [4] . These complications are thought to be the result of long-term, non-physiologically pulsatile dopamine-receptor stimulation [5] [6] [7] . As countermeasures designed to prolong the short duration of effect of LD, CD-LD has been formulated as a controlled-release (CR) preparation; and, IR CD-LD has been co-administered with a catechol-Omethyltransferase (COMT) inhibitor, e.g., entacapone [8] . Although each strategy has shown clinical benefit [9] [10] [11] , CR has not consistently yielded significant -off‖-time decreases or -on‖-time increases compared with those achieved with IR [12, 13] .
Additionally, patients often report a delayed onset of effect [14] [15] [16] [17] and a lessened predictability of response [14, 15] , necessitating supplemental IR doses [16] .
Nevertheless, global improvement ratings and patient preference findings have favored CR over IR [9, 15, 18] . For their part, COMT inhibitors may not reduce a patient's need for frequent LD dosing, and the peripheral pharmacokinetics of LD in patients using an adjunctive COMT inhibitor may not differ markedly from those taking CR alone [19] .
IPX066 (marketed in the United States as Rytary
® [carbidopa and levodopa] extended-release capsules) is an oral CD-LD formulation designed to achieve stable LD plasma concentrations within 1 hour of dosing and to maintain them for 4 to 5 hours before declining [20, 21] . In randomized, active-controlled, double-blind, double-dummy clinical trials, it has been evaluated for efficacy and safety in patients with advanced PD
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
7 previously treated with IR CD-LD (the ADVANCE-PD trial [22] ) or IR CD-LD plus entacapone (the ASCEND-PD trial [23] ). In both trials, IPX066 significantly decreased -off‖ time and increased -on‖ time without troublesome dyskinesia, while reducing administration frequency, and exhibited a safety profile similar to that of the active comparator. Both trials excluded patients who had been using CR CD-LD formulations.
Here, we report the findings of an open-label study of conversion to IPX066 followed by its long-term use in patients with advanced PD previously treated with CR CD-LD, alone or in combination with IR.
Methods

Study design
The study included 6 weeks of open-label, outpatient dose conversion (Dose Conversion period), 6 months of open-label maintenance (Extension 1), and, at certain study sites, a second period of open-label maintenance lasting a further 6 months (Extension 2). The baseline visit was defined as the visit immediately preceding the Dose Conversion period. Study visits were scheduled at screening, baseline, Weeks 3 and 6 of Dose Conversion, and every 3 months during Extensions 1 and 2 (or at early termination). To guide the initial dose conversion, investigators used the same dosing table that was tested previously in a study of advanced PD patients converting to IPX066 from IR CD-LD (Table 1 ) [22] . For all patients, the suggested initial IPX066 dosing frequency was 3 times daily (regardless of the patient's previous LD dosing frequency), at 6-hour intervals during waking hours. A fourth dose at bedtime was permitted. After initial conversion, the regimen could be adjusted at the investigator's discretion, but
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8 dosing more often than 5 times daily or at less than 4-hour intervals was discouraged. The overall goal was to minimize -off‖ time without causing troublesome dyskinesia.
Patients with a stable regimen (dose and dosing frequency) for at least 5 days before the end of Dose Conversion were eligible for Extension 1, and at selected study sites patients completing Extension 1 were eligible for Extension 2. During the study, patients were permitted to continue using amantadine, anticholinergics, selective monoamine oxidase B inhibitors (e.g., selegiline, rasagiline), and/or dopamine agonists, provided the regimens had remained stable for at least 4 weeks prior to screening. During the study, patients were not permitted to initiate use of any LD products (IR or CR), dopa-decarboxylase inhibitors, COMT inhibitors, apomorphine, or antipsychotics (including neuroleptic agents).
The study was registered with Clinicaltrials.gov (Identifier: NCT01411137).
Study participants
At screening, all patients were required to have PD based on United Kingdom
Parkinson's Disease Society Brain Bank criteria [24] , diagnosed at an age ≥30 years, and rated Hoehn & Yahr stage 1 to 4 [25] during the -on‖ state. Patients were to be taking LD at least 4 times daily, totaling at least 400 mg/day, in a regimen that had been stable for at least 4 weeks and included at least 1 daily dose of CR CD-LD. Patients were also required to have been experiencing an average of at least 2.5 hours per day of -off‖ time during the 2 weeks prior to screening per the patient's history. Patients with atypical or secondary parkinsonism, a Mini-Mental State Examination score <26 at screening, history of psychosis, malignant melanoma, narrow-angle glaucoma, severe hepatic
impairment, serum creatinine >1.5 times the upper limit of normal, or lack of LD responsiveness were excluded.
Regimen information
During Dose Conversion, the dose of IPX066 was monitored by weekly telephone calls and in-person visits at Weeks 3 and 6, and adjusted if needed. More frequent calls were suggested for the first 2 weeks to ensure appropriate dose adjustment. Patients were considered to have reached a stable regimen if they required no change in total daily IPX066 dosage or dosing frequency for at least 2 weeks. The first day of the stable regimen was used to calculate the time to stable dosing. After Dose Conversion, IPX066
usage was recorded periodically at follow-up clinic visits.
Clinical utility measures
Patient Global Impression of Improvement (PGI-I) and Clinician Global Impression of Improvement (CGI-I) scores [26] , and patient drug-preference assessments were obtained at the end of Dose Conversion and at 3 and 6 months during Extension 1 or at early discontinuation for patients not completing the study. At the same time points and also at baseline, patients completed the 8-item Parkinson's Disease Questionnaire (PDQ-8) [27] . For Extension 2, no clinical utility evaluations were planned or performed.
Exploratory clinical utility measures
Prior to Dose Conversion, a subset of patients was assessed by a computer-based motion sensor system called Objective Parkinson's Disease Measurement (OPDM) [28] , by an investigator assessment of patient motor state (Investigator Dyskinesia 
Safety measures
Following signing of the study informed consent, all spontaneously reported adverse events (AEs) were recorded by qualified site staff. The Columbia-Suicide Severity Rating
Scale (C-SSRS [31] ) was completed at each visit. Safety measures also included physical examination, vital signs, 12-lead electrocardiography, and clinical laboratory tests.
A C C E P T E D M A N U S C R I P T dropout rate, a total of 40 patients was to be enrolled.
Ethical conduct
The study was designed and conducted in full accordance with Good Clinical
Practice guidelines promulgated by the International Committee on Harmonisation and was approved by the appropriate Institutional Review Boards or Independent Ethics
Committees. Prior to study procedures, all patients provided written informed consent.
Results
Patient disposition
Patient disposition throughout the study is presented in Figure 1 . Eight clinical sites participated in the study, and 43 patients received study drug, with the first patient Safety). No patients discontinued during Extension 2.
Baseline characteristics
Patients' baseline demographic and clinical characteristics are summarized in Table   2 . Patients averaged 66.4 years of age. The mean duration of PD was 8.0 years, and most patients were rated as being at Hoehn & Yahr stage 2 or 3. Patients had been taking LD for an average of 6.6 years and had been using CR CD-LD for an average of 3.0 years in regimens that had been stable for an average of 13.5 months.
Baseline regimens and dose conversion
For enrolled patients and conversion completers, the proportion of total daily LD accounted for by CR is shown in Table 3 . Most patients had less than half of their total daily baseline LD dose accounted for by CR. For the 33 patients who completed dose conversion, LD daily dosage at baseline (as CR plus IR, or CR alone) and at the end of Dose Conversion (as IPX066) is presented in Table 4 . Overall, the mean at the end of Dose Conversion was 1906 mg/day compared with 1088 mg/day before conversion. Of the 33 completers, 30 had previously been taking both CR and IR and, among them, the mean (median) conversion ratio, defined as the ratio of IPX066 LD dose after conversion to the baseline LD dose, was 1.8 (1.7; range, 1.1-3.8). The other 3 patients had previously been taking LD solely as CR. Among them, the conversion ratios were 1.3, 1.6, and 1.8, for a mean of 1.5.
Among the 33 completers, the mean (median) IPX066 dosing frequency at the end of Dose Conversion was 3.5 (3.0) times/day, with 29 (87.9%) taking IPX066 either 3
A C C E P T E D M A N U S C R I P T ACCEPTED MANUSCRIPT
13 times/day (15 patients) or 4 times/day (14 patients). Among the 30 patients who had previously been taking both CR and IR, the mean (median) dosing frequencies of these agents had been 2.6 (1.0) and 4.6 (4.5) times/day, respectively. Among the 3 patients on CR alone, 1 patient had been taking it 4 times/day, and 2 patients 5 times/day.
Of the 33 conversion completers, 29 (87.9%) had achieved a stable dosage in an average time of 25 days (range, 1-45 days).
Subsequent dosing
Among the 32 patients who entered Extension 1, the mean dosage of LD (in IPX066) at month 6 or early withdrawal was 1833 mg/day compared with 1939 mg/day among these patients at the end of Dose Conversion. Nine patients (28.1%) maintained the dosage established during Dose Conversion, and another 5 (15.6%) were on a dosage changed by ≤100 mg/day (an increase in 3 patients, a decrease in 2 patients). Seven patients (21.9%) had increases >300 mg/day, and 6 patients (18.8%) had decreases >300 mg/day. Twenty-eight patients (87.5%) were taking IPX066 ≤4 times/day.
Among the 12 patients who entered (and completed) Extension 2, the mean dosage of LD (in IPX066) at the end of this additional 6 months of treatment was 1605 mg/day compared with 1604 mg/day and 1642 mg/day among these patients at the end of Dose Conversion and the end of Extension 1, respectively. In 5 patients (41.7%), dosage at the end of Extension 2 remained unchanged (4 patients) or had changed by ≤100 mg/day (a decrease in 1 patient) from its value at the end of Dose Conversion. Two patients (16.7%) had increases >300 mg/day, and 2 patients (16.7%) had decreases >300 mg/day. Ten of 12 patients (83.3%) were still taking IPX066 ≤4 times/day.
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Use of concomitant medications exhibited little change during the study (data not shown).
Clinical utility
PGI-I and CGI-I findings are presented in Figure 2 . On the PDQ-8, the mean (standard deviation [SD]) total score decreased (improved) slightly during the study, from 9.6 (5.5) at baseline to 8.1 (4.6) at the end of Dose Conversion and 9.0 (5.9) after Extension 1, but these improvements were not statistically significant.
Exploratory clinical utility
The 12 patients (7 men and 5 women) in the OPDM cohort had an average (SD) age 
Safety
During the study, 35 patients (81.4% of the 43 treated patients) reported AEs (Table 6 ).
Those AEs reported by ≥10.0% of treated patients were urinary tract infection, nausea, anxiety, and fall. Dyskinesia and viral upper respiratory tract infection were each reported by 9.3%, and hallucination, orthostatic hypotension, and tremor were each reported by 7.0%.
Three patients (7.0% of the 43 treated patients) reported AEs rated as severe:
orthostatic hypotension in 2 patients (1 instance judged to be related, and the other unrelated, to study drug) and sepsis in 1 patient (judged to be unrelated to study drug).
Six patients (14.0%) had serious AEs (SAEs). The only SAE reported by more than 1 patient was orthostatic hypotension, in the aforementioned 2 patients. The other SAEs, each reported by 1 patient, were anxiety (related), atrial fibrillation (unrelated), back pain (unrelated), cerebrovascular accident (unrelated), exacerbation of PD (related), and sepsis (unrelated). One patient died (during Dose Conversion, after hospice admission for PD complications classified as unrelated to study drug).
Seven patients (16.3% of the 43 treated patients) discontinued their study participation due to AEs, all of which were classified as related to study drug. AEs reported as the reason for discontinuation were abdominal pain, agitation, anxiety, confusional state, diarrhea, dyskinesia, dystonia, hallucination, headache, nausea, orthostatic hypotension, vision blurred, and vomiting. Only nausea (n = 3) was listed as the reason for discontinuation in more than 1 patient (Figure 1) .
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17 C-SSRS findings did not suggest any new suicidal ideation or behavior during the study. Physical examination, vital signs, electrocardiography, and clinical laboratory tests identified no clinically relevant patterns.
Discussion
Although small and open-label, this study provides guidance for switching PD patients to IPX066 from CR CD-LD therapy. At the end of IPX066 Dose Conversion, the mean conversion ratio was 1.8 among patients previously on CR plus IR and 1.5 among the 3 patients previously on CR alone. In an earlier study of conversion from IR CD-LD [22] , the mean ratio following IPX066 dose conversion was 2.1 [32] ; and in a study comparing IPX066 and CD-LD plus entacapone [23, 32] , it was 2.8. These differences likely reflect the pharmacokinetic differences between IPX066 and other LD formulations [21] .
The IPX066-associated LD dose increase may be necessary to provide a more sustained LD plasma level, i.e., a -filling in‖ of the troughs in LD concentration commonly observed between doses of typical LD therapy. Despite the higher systemic LD exposure, the incidence of dyskinesia as a reported AE was low, as has also been found in studies of patients switched to IPX066 from IR CD-LD [22] or IR CD-LD plus entacapone [23] .
During Dose Conversion, almost 3 times as many patients (63.0%) preferred IPX066 compared with those (23.0%) who preferred their previous treatment; this preference for IPX066 persisted through Extension 1 (66.0% vs 13.0%). For both of these study phases, PGI findings were corroborative (with 61% of conversion participants and 69% of Extension-1 participants rating themselves as being improved). AEs during IPX066 treatment for up to 58 weeks were generally consistent with those expected in a population of aging patients receiving dopaminergic pharmacotherapy for advanced PD, and were similar to those reported previously in advanced PD patients receiving IPX066 [22, 23] or IR CD-LD [1, 33] . Among AE-related discontinuations, only nausea was reported in more than 1 patient. However, the incidence of nausea decreased throughout the study (Table 6 ).
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The present study is limited by its open-label design and small patient enrollment numbers, hampering comparisons with the aforementioned double-blind clinical trials [22, 23] . Indeed, the study's OPDM and UPDRS findings pertained to only 12 patients.
Moreover, the OPDM and UPDRS findings were obtained after single, pre-specified, open-label doses of IPX066 and CR CD-LD administered prior to the establishment of each patient's individualized IPX066 regimen. Additionally, the present study was not a
19 direct comparison between IPX066 and a standard CR CD-LD formulation in that only 3 patients were using CR as their sole LD therapy.
On the other hand, the study's post-conversion treatment lasted up to 12 months.
The study's length and its absence of formal restrictions on the conduct of dose conversion match real-world clinical practice more closely than is permitted by the constraints of a randomized, controlled trial-which, to compare LD formulations with differing dosing frequencies, would require frequent dosing of active treatments and placebos in elaborate combinations. The study suggests that the initial dose conversion table tested for switching from IR CD-LD [22] can also be used for patients on CR CD-LD alone or in combination with IR CD-LD, with dose adjustment as needed during the individual patient's conversion.
Conclusions
The results of this small, open-label study suggest that advanced PD patients using CR CD-LD, alone or with IR CD-LD, can be safely switched to a stable IPX066 regimen with reduction of dosing frequency and improvement in overall clinical benefit. IPX066 may be an effective therapeutic option for patients with advanced PD being treated with CR CD-LD.
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A C C E P T E D M A N U S C R I P T patients with a pre-dose and at least 1 post-dose assessment of both drugs. For mobility score, increases represent improvement; n = 10 at 4 hours and n = 11 otherwise. For dexterity score, decreases represent improvement; n = 8 at 2 hours, n = 7 at 6 hours, and n = 9 otherwise. For UPDRS Part III score, decreases represent improvement; all cohort patients provided data (n = 12). 
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